Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
2(40%)
Results Posted
100%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_3
1
20%
Ph phase_4
2
40%
Ph early_phase_1
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)

Trials by Status

terminated120%
active_not_recruiting120%
recruiting120%
completed240%

Recent Activity

2 active trials
Showing 5 of 5
active_not_recruitingphase_3

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

NCT06868264
recruitingearly_phase_1

Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania

NCT06159504
terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

NCT02510300
completedphase_4

deLIVER: Direct Acting Antiviral Effects on the Liver

NCT02938013
completedphase_4

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

NCT03512210

Clinical Trials (5)

Showing 5 of 5 trials
NCT06868264Phase 3

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

Active Not Recruiting
NCT06159504Early Phase 1

Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania

Recruiting
NCT02510300

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Terminated
NCT02938013Phase 4

deLIVER: Direct Acting Antiviral Effects on the Liver

Completed
NCT03512210Phase 4

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5